SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Promoter entity plans to delist Fresenius Kabi Oncology from the bourses

18 Apr 2013 Evaluate

Fresenius Kabi Oncology’s (FKOL) promoter entity Fresenius Kabi (Singapore) (FKSL) is planning to delist its Indian arm through acquiring 19% stake held by the public. FKSL intends to pay an indicative price of upto Rs 130 per share to acquire the scrips offered to it in the delisting offer.

Fresenius Kabi (Singapore) holds 81% of the total stake in the Indian arm.

Fresenius Kabi Oncology manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.

Peers
Company Name CMP
Sun Pharma Inds. 1654.30
Dr. Reddys Lab 1216.90
Cipla 1229.00
Zydus Lifesciences 931.10
Lupin 2316.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×